Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011, Article ID 842842, 10 pages
http://dx.doi.org/10.1155/2011/842842
Research Article

Involvement of the Soluble Urokinase Receptor in Chondrosarcoma Cell Mobilization

1Department of Experimental Oncology, National Cancer Institute of Naples, Via Mariano Semmola 1, 80131 Naples, Italy
2Department of Human Pathology, National Cancer Institute of Naples, Via Mariano Semmola 1, 80131 Naples, Italy
3Department of Surgical Oncology, National Cancer Institute of Naples, Via Mariano Semmola 1, 80131 Naples, Italy
4Department of Medical Oncology, National Cancer Institute of Naples, Via Mariano Semmola 1, 80131 Naples, Italy

Received 26 August 2010; Revised 3 November 2010; Accepted 1 December 2010

Academic Editor: Charles Scoggins

Copyright © 2011 Katia Bifulco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. V. M. G. Bovée, P. C. W. Hogendoorn, J. S. Wunder, and B. A. Alman, “Cartilage tumours and bone development: molecular pathology and possible therapeutic targets,” Nature Reviews Cancer, vol. 10, no. 7, pp. 481–488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Y. Giuffrida, J. E. Burgueno, L. G. Koniaris, J. C. Gutierrez, R. Duncan, and S. P. Scully, “Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database,” Journal of Bone and Joint Surgery - Series A, vol. 91, no. 5, pp. 1063–1072, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Fiorenza, A. Abudu, R. J. Grimer et al., “Risk factors for survival and local control in chondrosarcoma of bone,” Journal of Bone and Joint Surgery - Series B, vol. 84, no. 1, pp. 93–99, 2002. View at Google Scholar · View at Scopus
  4. G. Ayala, C. Liu, R. Nicosia, S. Horowitz, and R. Lackman, “Microvasculature and VEGF expression in cartilaginous tumors,” Human Pathology, vol. 31, no. 3, pp. 341–346, 2000. View at Google Scholar · View at Scopus
  5. H. Gelderblom, P. C. W. Hogendoorn, S. D. Dijkstra et al., “The clinical approach towards chondrosarcoma,” Oncologist, vol. 13, no. 3, pp. 320–329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Duffy and C. Duggan, “The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer,” Clinical Biochemistry, vol. 37, no. 7, pp. 541–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Mondino and F. Blasi, “uPA and uPAR in fibrinolysis, immunity and pathology,” Trends in Immunology, vol. 25, no. 8, pp. 450–455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Pillay, C. R. Dass, and P. F. M. Choong, “The urokinase plasminogen activator receptor as a gene therapy target for cancer,” Trends in Biotechnology, vol. 25, no. 1, pp. 33–39, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. B. R. Binder, J. Mihaly, and G. W. Prager, “uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view,” Thrombosis and Haemostasis, vol. 97, no. 3, pp. 336–342, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. M. S. Pepper, “Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 7, pp. 1104–1117, 2001. View at Google Scholar · View at Scopus
  11. H. W. Smith and C. J. Marshall, “Regulation of cell signalling by uPAR,” Nature Reviews Molecular Cell Biology, vol. 11, no. 1, pp. 23–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. V. Carriero, P. Franco, S. Del Vecchio et al., “Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies,” Cancer Research, vol. 54, no. 20, pp. 5445–5454, 1994. View at Google Scholar · View at Scopus
  13. K. Danø, N. Behrendt, G. Høyer-Hansen et al., “Plasminogen activation and cancer,” Thrombosis and Haemostasis, vol. 93, no. 4, pp. 676–681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. G. Rasch, I. K. Lund, C. E. Almasi, and G. Hoyer-Hansen, “Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer,” Frontiers in Bioscience, vol. 13, pp. 6752–6762, 2008. View at Google Scholar · View at Scopus
  15. M. Ploug and V. Ellis, “Structure-function relationships in the receptor for urokinase-type plasminogen activator: comparison to other members of the Ly-6 family and snake venom α-neurotoxins,” FEBS Letters, vol. 349, no. 2, pp. 163–168, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Resnati, I. Pallavicini, J. M. Wang et al., “The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1359–1364, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Gargiulo, I. Longanesi-Cattani, K. Bifulco et al., “Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide,” Journal of Biological Chemistry, vol. 280, no. 26, pp. 25225–25232, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Barinka, G. Parry, J. Callahan et al., “Structural basis of interaction between urokinase-type plasminogen activator and its receptor,” Journal of Molecular Biology, vol. 363, no. 2, pp. 482–495, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Selleri, N. Montuori, P. Ricci et al., “In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer,” Cancer Research, vol. 66, no. 22, pp. 10885–10890, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. V. Carriero, I. Longanesi-Cattani, K. Bifulco et al., “Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis,” Molecular Cancer Therapeutics, vol. 8, no. 9, pp. 2708–2717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Sidenius and F. Blasi, “The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy,” Cancer and Metastasis Reviews, vol. 22, no. 2-3, pp. 205–222, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Henić, C. Borgfeldt, IB. J. Christensen, B. Casslén, and G. Høyer-Hansen, “Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer,” Clinical Cancer Research, vol. 14, no. 18, p. 5785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. F. Shariat, C. G. Roehrborn, J. D. McConnell et al., “Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis,” Journal of Clinical Oncology, vol. 25, no. 4, pp. 349–355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Sidenius, C. F. M. Sier, and F. Blasi, “Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo,” FEBS Letters, vol. 475, no. 1, pp. 52–56, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Taubert, P. Würl, T. Greither et al., “Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients,” British Journal of Cancer, vol. 102, no. 4, pp. 731–737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. R. Antonescu and M. Ladanyi, Pathology and Genetics of Tumors of Soft and Bone, World Health Organization Classification of Tumors, IARC Press, Lyon, France, 2002.
  27. I. Silvestri, I. L. Cattani, P. Franco et al., “Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating αvβ5 vitronectin receptor cell surface expression,” International Journal of Cancer, vol. 102, no. 6, pp. 562–571, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Bifulco, A. De Chiara, F. Fazioli et al., “Cell invasiveness in sarcomas: a possibly useful clinical correlation,” Tumori, vol. 94, no. 4, pp. 505–510, 2008. View at Google Scholar · View at Scopus
  29. M. V. Carriero, S. Del Vecchio, M. Capozzoli et al., “Urokinase receptor interacts with α(v)β vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer,” Cancer Research, vol. 59, no. 20, pp. 5307–5314, 1999. View at Google Scholar · View at Scopus
  30. K. Bifulco, I. Longanesi-Cattani, M. Gala et al., “The soluble form of urokinase receptor promotes angiogenesis through its SER(88) -ARG-SER-ARG-TYR(92) chemotactic sequence,” Journal of Thrombosis and Haemostasis, vol. 8, no. 12, pp. 2789–2799, 2010. View at Google Scholar · View at Scopus
  31. N. Montuori, K. Bifulco, M. V. Carriero et al., “The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor,” Cellular and Molecular Life Sciences. In press.
  32. C. Selleri, N. Montuori, P. Ricci et al., “Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization,” Blood, vol. 105, no. 5, pp. 2198–2205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Albini, Y. Iwamoto, and H. K. Kleinman, “A rapid in vitro assay for quantitating the invasive potential of tumor cells,” Cancer Research, vol. 47, no. 12, pp. 3239–3245, 1987. View at Google Scholar · View at Scopus